Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

RSS icon

FDA says ‘no’ to serelaxin for heart failure

The FDA followed the lead of its counterpart in Europe by rejecting a bid from Novartis to approve serelaxin as a treatment for acute heart failure. The FDA stated that it needed more proof of the drug’s efficacy.

Boston Scientific snags Bayer’s peripheral unit for $415M

Boston Scientific will buy the interventional device division at Bayer AG for $415 million. The acquisition will let Boston Scientific widen its portfolio of technologies used to treat coronary and peripheral vascular disease.

Elixir Medical receives CE Mark approval for the breakthrough fully bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System

Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE (Conformité Européenne) Mark approval for its DESolve® 100 Novolimus Eluting Bioresorbable Coronary Scaffold System.

FDA study weighs in favor of dabigatran

The FDA maintained its position on the safety of the anticoagulant dabigatran after completing a study that included an older patient population. Based on the results, the agency said it would make no changes in its recommendations or to the labeling.

Therapy sought to reduce major risk from minor bleeding that can follow stroke

Bleeding into the brain following a stroke doesn't have to be big to be bad, says a researcher exploring a therapy to eliminate the major risk of minor bleeding.

Feds scrutinizing two cardiac device makers

Two manufacturers are under the federal magnifying glass with investigations involving implantable cardiac devices. The investigations are unrelated.

HRS.14: ACE inhibitors, ARBs lower incidence of appropriate shocks

ACE inhibitors and ARBs have a protective effect on patients with cardiomyopathy who receive implantable cardioverter-defibrillators (ICDs), according to an analysis presented May 8 at the Heart Rhythm Society scientific session in San Francisco.

New data show that defibrillators programmed to wait longer to deliver therapy are safe for secondary prevention ICD patients with Medtronic SmartShock technology

Medtronic, Inc. today announced the results from the first prospective randomized clinical trial to show that Medtronic implantable cardioverter defibrillators (ICDs) can safely extend detection times before triggering therapy in secondary prevention patients. The results of the PainFree SST sub-study, unveiled today as a late-breaking presentation at the Heart Rhythm Society's 35th Annual Scientific Sessions, demonstrate that physicians can choose to program ICDs with delayed detection interval settings without compromising safety for high-risk patients.

Displaying 7441 - 7448 of 10742

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.